An Expert Review on The Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer
Journal CME
1 AMA PRA Category 1 Credit™ ...Faculty
OVERVIEW
An Expert Review on The Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer is organized by American Society for Radiation Oncology (ASTRO).
Course opens: 05/12/2022
Course expires: 05/11/2024
Description: This journal activity provides practitioners with the knowledge needed to utilize relugolix in combination with radiation therapy in daily practice.
Learning Objectives :
Upon completion of this activity, participants should be able to:
• Describe the relative benefits of relugolix compared with degarelix and leuprolide, identify patients eligible for therapy, and determine the optimal duration of use based on expert recommendations.
Additional details will be posted as soon as information is available.
ACCREDITATION & CREDITS
Accreditation Statement:
1.00 Certificate of Attendance
This activity was designated for 1.00 AMA PRA Category 1 Credit™.
1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
TARGET AUDIENCE
OncologistsUrologistsResidentsRadiation OncologistsSPECIALITIES
OncologyUrologyRELATED ONLINE COURSES
Quick Links